Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A, Doesburg W
Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkhla University, Thailand.
Int J Fertil Menopausal Stud. 1996 Jul-Aug;41(4):423-9.
To compare the effects of a low-dose oral contraceptive containing desogestrel (Marvelon) and an anti-androgenic preparation containing cyproterone acetate (Diane) in Oriental women suffering from acne.
In an open-label, bi-center, randomized study, 32 women using Marvelon and 34 using Diane were followed for 6 treatment cycles. The measured variables were objective and subjective severity of acne, and related biochemical variables such as sex hormone-binding globulin and free and total testosterone.
In Center A, with both preparations a decrease in mean objective acne score was observed, reaching statistical significance with Diane (P < .05). In addition, there was a significant between group difference at cycle 6 (P < .05). In Center B, a consistent and significant decrease in mean acne score was observed with Marvelon after three and six treatment cycles (P < .05 and P < .01) and with Diane after six treatment cycles (P < .001). There were no significant between-group differences. The decrease in percentage of severe/moderate acne was statistically significant with Marvelon in Center B (P = 0.002) and with Diane in Centers A (P = 0.014) and B (P = 0.004). Both preparations increased plasma levels of sex hormone binding globulin and seemed to decrease those of total and free testosterone, but no statistically significant relationships between acne severity and biochemical variables could be detected.
Both Marvelon and Diane are effective in the treatment of acne in Oriental women who also need reliable contraception, without marked differences between the preparations.
比较含去氧孕烯的低剂量口服避孕药（妈富隆）和含醋酸环丙孕酮的抗雄激素制剂（达英）对患有痤疮的东方女性的治疗效果。
在一项开放标签、双中心、随机研究中，32名服用妈富隆的女性和34名服用达英的女性接受了6个治疗周期的随访。测量变量包括痤疮的客观和主观严重程度，以及相关生化变量，如性激素结合球蛋白、游离睾酮和总睾酮。
在A中心，两种制剂均使平均客观痤疮评分下降，达英组达到统计学显著性（P < 0.05）。此外，在第6周期两组间存在显著差异（P < 0.05）。在B中心，服用妈富隆的女性在3个和6个治疗周期后平均痤疮评分持续显著下降（P < 0.05和P < 0.01），服用达英的女性在6个治疗周期后平均痤疮评分显著下降（P < 0.001）。两组间无显著差异。在B中心，服用妈富隆的女性重度/中度痤疮百分比下降具有统计学显著性（P = 0.002），在A中心和B中心，服用达英的女性重度/中度痤疮百分比下降具有统计学显著性（P = 0.014和P = 0.004）。两种制剂均使血浆性激素结合球蛋白水平升高，总睾酮和游离睾酮水平似乎下降，但未检测到痤疮严重程度与生化变量之间存在统计学显著关系。
妈富隆和达英对需要可靠避孕的东方痤疮女性均有效，两种制剂之间无明显差异。
